CNBX Pharmaceuticals Inc.

OTCPK:CNBX Stock Report

Market Cap: US$186.7k

CNBX Pharmaceuticals Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Eyal Barad

Chief executive officer

US$200.5k

Total compensation

CEO salary percentage100.0%
CEO tenure6.9yrs
CEO ownershipn/a
Management average tenure6yrs
Board average tenure5.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Eyal Barad's remuneration changed compared to CNBX Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Aug 31 2024US$201kUS$201k

-US$695k

May 31 2024n/an/a

-US$1m

Feb 29 2024n/an/a

-US$1m

Nov 30 2023n/an/a

-US$4m

Aug 31 2023US$254kUS$227k

-US$4m

May 31 2023n/an/a

-US$4m

Feb 28 2023n/an/a

-US$4m

Nov 30 2022n/an/a

-US$3m

Aug 31 2022US$269kUS$246k

-US$4m

May 31 2022n/an/a

-US$4m

Feb 28 2022n/an/a

-US$5m

Nov 30 2021n/an/a

-US$4m

Aug 31 2021US$269kUS$253k

-US$3m

May 31 2021n/an/a

-US$3m

Feb 28 2021n/an/a

-US$3m

Nov 30 2020n/an/a

-US$3m

Aug 31 2020US$241kUS$222k

-US$7m

May 31 2020n/an/a

-US$8m

Feb 29 2020n/an/a

-US$8m

Nov 30 2019n/an/a

-US$3m

Aug 31 2019US$276kUS$258k

US$1m

May 31 2019n/an/a

US$2m

Feb 28 2019n/an/a

US$1m

Nov 30 2018n/an/a

-US$4m

Aug 31 2018US$207kUS$207k

-US$4m

Compensation vs Market: Eyal's total compensation ($USD200.53K) is below average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Eyal's compensation has been consistent with company performance over the past year.

CEO

Eyal Barad (59 yo)

6.9yrs

Tenure

US$200,532

Compensation

Mr. Eyal Barad is the Co- Founder of CNBX Pharmaceuticals Inc. (formerly known as Cannabics Pharmaceuticals Inc.) and has been its Chief Executive Officer since January 29, 2018 and Director since November...

Leadership Team

NamePositionTenureCompensationOwnership
Gabriel Yariv
President5.2yrsUS$327.93kno data
Eyal Barad
Co-Founder6.9yrsUS$200.53kno data
Uri Ben-Or
Chief Financial Officer8.1yrsUS$33.97kno data
Sanja Goldberg
Chief Technology Officer2.4yrsUS$48.12kno data
Noam Permont
Vice President of Public Relations & Investor Relationsno datano datano data
Sigalit Ariely-Portnoy
Senior Advisor of Regulation7.8yrsno datano data
Tal Mofkadi
Financial Advisor & Member of Advisory Boardno datano datano data
Yasha Borstein
Chief Data Officer6.8yrsno datano data
Yaakov Waksman
Head of Cannabidiol Research5yrsno datano data
Ilya Reznik
Head of Neuropsychiatry Development3.3yrsno datano data
Lior Eshdat
Member of Scientific Advisory Board & VP of IPno datano datano data

6.0yrs

Average Tenure

59yo

Average Age

Experienced Management: CNBX's management team is seasoned and experienced (6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Gabriel Yariv
President5.2yrsUS$327.93kno data
Eyal Barad
Co-Founder7.1yrsUS$200.53kno data
Sigalit Ariely-Portnoy
Senior Advisor of Regulation7.8yrsno datano data
Tal Mofkadi
Financial Advisor & Member of Advisory Board7.8yrsno datano data
Lior Eshdat
Member of Scientific Advisory Board & VP of IPno datano datano data
Zamir Halpern
Member of Advisory Board4.7yrsno datano data
Gil Feiler
Head of Advisory Board7.8yrsUS$49.85kno data
Amos Toren
Member of Advisory Board7.8yrsno datano data
Erez Scapa
Member of Advisory Board4.5yrsno datano data
Dana Ben-Ami Shor
Member of Advisory Board4.3yrsno datano data
Caroline Robert
Member of Advisory Board3.3yrsno datano data
Sigal Tavor
Member of Advisory Board3.3yrsno datano data

5.2yrs

Average Tenure

59.5yo

Average Age

Experienced Board: CNBX's board of directors are considered experienced (5.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 13:58
End of Day Share Price 2024/12/24 00:00
Earnings2024/08/31
Annual Earnings2024/08/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CNBX Pharmaceuticals Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution